Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas


Journal Article

Pancreatic cancer is resistant to most chemotherapeutic regimens. Based upon evidence of synergy between 5-fluorouracil (5-FU) and cisplatin (CDDP), and of enhanced 5-FU activity in the presence of leucovorin in other neoplasms, a phase II study of CDDP, 5-FU, and leucovorin was conducted to determine the efficacy of this regimen in patients with unresectable adenocarcinomas of the pancreas. Nineteen patients were enrolled, and all were evaluable for toxicity and response. One complete and two partial responses were observed (15.8%). Adverse effects were reversible and tolerable. This regimen has limited activity against pancreatic cancer, and cannot be recommended as standard therapy in this disease.

Duke Authors

Cited Authors

  • Jones, DV; Sugarman, SM; Markowitz, AB; Levin, B; Abbruzzese, JL; Evans, DB; Charnsangavej, C; Smith, R; Patt, YZ

Published Date

  • January 1, 1995

Published In

Volume / Issue

  • 2 / 6

Start / End Page

  • 1121 - 1123

International Standard Serial Number (ISSN)

  • 1021-335X

Citation Source

  • Scopus